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Objective: Acute lower extremity ischemia (ALI) is a common vascular surgery emergency associated with high rates of
morbidity and mortality. The purpose of this study was to assess contemporary trends in the incidence of ALI, the
methods of treatment, and the associated mortality and amputation rates in the U.S. Medicare population.
Methods: This was an observational study using Medicare claims data between 1998 and 2009. Outcomes examined
included trends in the incidence of ALI; trends in interventions for ALI; and trends in amputation, mortality, and
amputation-free survival rates.
Results: Between 1998 and 2009, the incidence of hospitalization for ALI decreased from 45.7 per 100,000 to 26.0 per
100,000 (P for trend < .001). The percentage of patients undergoing surgical intervention decreased from 57.1% to
51.6% (P for trend < .001), whereas the percentage of patients undergoing endovascular interventions increased from
15.0% to 33.1% (P for trend < .001). In-hospital mortality rates decreased from 12.0% to 9.0% (P for trend < .001),
whereas 1-year mortality rates remained stable at 41.0% and 42.5% (P for trend not signiﬁcant). In-hospital amputation
rates remained stable at 8.1% and 6.4% (P for trend not signiﬁcant), whereas 1-year amputation rates decreased from
14.8% to 11.0% (P for trend < .001). In-hospital amputation-free survival after hospitalization for ALI increased from
81.2% to 85.4% (P for trend < .001); however, 1-year amputation-free survival remained unchanged.
Conclusions: Between 1998 and 2009, the incidence of ALI among the U.S. Medicare population declined signiﬁcantly,
and the percentage of patients treated with endovascular techniques markedly increased. During this time, 1-year
amputation rates declined. Furthermore, although in-hospital mortality rates declined after presentation with ALI,
1-year mortality rates remained unchanged. (J Vasc Surg 2014;60:669-77.)Acute lower extremity ischemia (ALI) resulting from
arterial thrombosis, arterial embolus, or bypass graft
thrombosis remains one of the most common vascular sur-
gery emergencies. The postprocedure rates of mortality
and limb loss have traditionally been reported to be as
high as 20% to 40% and 12% to 50%, respectively.1-8 How-
ever, the contemporary incidence of patients presenting
with ALI and the outcomes after intervention in this pa-
tient population remain ill-deﬁned. This is an especially
relevant question in view of the substantial increase in the
use of endovascular therapy during the past decade.
Conventional treatment of patients with ALI has
been systemic anticoagulation and emergent open surgical
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://dx.doi.org/10.1016/j.jvs.2014.03.244Endovascular therapy and, more speciﬁcally, the use of
catheter-directed thrombolytic therapy were initially
described in several randomized controlled trials in the
mid-1990s.9-14 An endovascular therapeutic approach of-
fers a less invasive alternative to conventional open surgical
revascularization but often requires more time to restore
arterial ﬂow and can be associated with higher rates of
hemorrhage. Despite these limitations, initial randomized
trials reported that this less invasive approach for the treat-
ment of ALI was associated with equivalent if not lower
mortality and amputation rates compared with conven-
tional surgery.9-13 Since the time of these initial reports,
however, no large studies have been performed to assess
the diffusion of endovascular therapy for ALI or contempo-
rary outcomes for endovascular and conventional surgical
therapy for ALI. The primary objectives of this study
were to examine trends in the incidence of ALI, to assess
the relative use of open surgical vs endovascular therapy
for ALI, and to document trends in the amputation and
mortality rates for elderly Medicare beneﬁciaries presenting
with ALI.
METHODS
Data sources. Data were obtained from the 1998-
2009 Medicare Provider Analysis and Review (MedPAR)
ﬁles, which contain hospital discharge abstracts for the
acute care hospitalizations of all Medicare beneﬁciaries
with Part A coverage. The data include admission and669
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tion of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) diagnosis and procedure codes, and
discharge disposition. The MedPAR ﬁles were linked to
Medicare denominator ﬁles, which include information on
beneﬁciaries’ date of birth, gender, race/ethnicity (cate-
gorized as black, white, or other), enrollment status, region
of residence (Midwest, Northeast, South, or West), and
vital status (including date of death).
Study sample. The initial patient population was
deﬁned by identifying Medicare fee-for-service beneﬁ-
ciaries 65 years or older. Patients residing outside the
United States as well as patients enrolled in a Medicare
health maintenance organization during the study period
were excluded as MedPAR data may not capture complete
health care claims data for these individuals.
Hospitalizations for ALI were identiﬁed on the basis of
the presence of the following two criteria: (1) a principal
discharge diagnosis of lower extremity embolism or throm-
bosis deﬁned as ICD-9-CM codes 444.0 (abdominal aortic
embolism and thrombosis), 444.22 (lower extremity em-
bolism and thrombosis), and 444.81 (iliac artery embolism
and thrombosis); and (2) admission type classiﬁed as either
urgent or emergent in the MedPAR ﬁles.
To determine subsequent in-hospital interventions, the
following ICD-9 procedural codes were used to capture
surgical interventions: 38.06 (incision of vessel, abdominal
arteries), 38.08 (incision of vessel, lower limb arteries),
38.16 (endarterectomy, abdominal arteries), 38.18 (endar-
terectomy, lower limb arteries), 38.46 (resection of
abdominal vessels, replacement), 38.48 (resection of lower
limb artery, replacement), 39.25 (aortoiliac-femoral
bypass), 39.29 (other peripheral shunt/bypass), 39.49
(other revision of vascular procedure), 39.56 (repair of
blood vessel with tissue graft patch), and 39.57 (repair of
blood vessel with synthetic graft patch). We deﬁned endo-
vascular procedures by the following ICD-9 procedure
codes: 99.10 (thrombolytic therapy), 39.50 (angioplasty
or atherectomy of noncoronary vessel), 39.90 (insertion
of noncoronary artery stent or stents), and 00.55 (insertion
of drug-eluting stent of other peripheral vessels). Individ-
uals who underwent both an endovascular and a surgical
procedure for limb salvage during the same hospitalization
were excluded. In addition, the ICD-9 procedure codes
used to deﬁne major amputations were as follows: 84.13
(disarticulation of ankle), 84.14 (amputation of ankle
through malleoli of tibia and ﬁbula), 84.15 (other amputa-
tion below knee), 84.16 (disarticulation of knee), and
84.17 (amputation above knee). For individuals with
more than one hospitalization for ALI, only the ﬁrst hospi-
talization was included and was considered the index event.
Risk factors. Information on the clinical comorbidities
used in the Klabunde adaptation of the Charlson comor-
bidity index were obtained using a 2-year look-back win-
dow from the index admission date.15,16 The comorbidities
included chronic heart disease, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, atrial
ﬁbrillation or atrial ﬂutter, dementia, chronic pulmonarydisease, paralysis, ulcer disease, moderate or severe liver
disease, chronic renal failure, chronic liver disease or
cirrhosis, rheumatologic disease, diabetes mellitus, hyper-
tension, hyperlipidemia, acquired immunodeﬁciency syn-
drome, and history of cancer.
Outcomes. Outcomes included the incidence of
hospitalizations for ALI; rates of open vascular and endo-
vascular procedures; and in-hospital, 30-day, and 1-year
amputation, mortality, and amputation-free survival rates.
Statistical analysis. The annual incidence of hospital-
ization for ALI was calculated for each year from 1998 to
2009 and is reported as number of events per 100,000
Medicare beneﬁciaries. Rates were standardized to the
age distribution of the year 2000 population. The demo-
graphic and clinical characteristics of individuals hospital-
ized for ALI are presented separately for each of three
time windows: 1998-2001, 2002-2005, and 2006-2009.
We used analysis of variance for comparisons of continuous
variables and c2 tests for comparisons of categorical
variables. We calculated in-hospital, 30-day, and 1-year
amputation, mortality, and amputation-free survival rates.
The 30-day and 1-year rates were calculated from the date
of admission. Risk-adjusted rates were calculated by uni-
variate analysis and multivariable logistic regression analysis
controlling for age, gender, race, region, and medical
comorbidities.
The signiﬁcance of trends in ALI incidence and out-
comes were assessed by including year as a continuous var-
iable in regression models. Analyses were performed with
the SAS 9.2 statistical package (SAS Institute, Cary, NC).
P values < .05 were considered statistically signiﬁcant
with two-sided tests for all analyses.RESULTS
Study population. We identiﬁed a total of 99,982
hospitalizations for ALI between 1998 and 2009. During
the study period, the mean age was 80.6 years, 60.7%
were female, and 8.6% were black (Table I). Over time,
the portion of the population older than 80 years increased
substantially, from 50.5% in 1998 to 58.9% in 2009
(P < .001 for trend). The gender and race distributions
remained relatively stable over time.
Patients hospitalized for ALI had a high burden of
known risk factors for ALI or peripheral vascular disease,
the most prevalent being congestive heart failure, chronic
heart disease, peripheral vascular disease, hypertension, dia-
betes, hyperlipidemia, chronic obstructive pulmonary dis-
ease, cerebrovascular disease, and atrial ﬁbrillation.
During the study period, there was a signiﬁcant increase
in the prevalence of multiple comorbidities, including dia-
betes, atrial ﬁbrillation, hypertension, and hyperlipidemia.
Incidence of ALI. Hospitalizations for ALI decreased
from 45.7 per 100,000 in 1998 to 26.0 per 100,000 in
2009 (P for trend < .001). In men, there was a decrease
from 46.5 per 100,000 in 1998 to 23.8 per 100,000 in
2009; in women, there was a decrease from 45.2 per
100,000 in 1998 to 27.6 per 100,000 in 2009 (Fig 1).
Table I. Characteristics of U.S. Medicare patients with acute lower extremity ischemia (ALI) from 1998 to 2009
1998-2001, No. (%) 2002-2005, No. (%) 2006-2009, No. (%) P value for trend
Age, years
65-69 3509 (8.9) 2792 (8.5) 2211 (8.0) .001
70-74 7390 (18.6) 5464 (16.7) 4154 (15.1) .000
75-79 8702 (21.9) 6676 (20.4) 4948 (18.0) .000
80-84 8215 (20.7) 7063 (21.5) 5937 (21.6) .007
$85 11,839 (29.9) 10,800 (32.9) 10,282 (37.4) .000
Gender
Male 15,719 (39.6) 12,999 (39.6) 10,610 (38.5) .006
Race
White 34,874 (87.9) 28,585 (87.2) 24,258 (88.1) .001
Black 3450 (8.7) 2933 (8.9) 2215 (8.0) .000
Other 1331 (3.4) 1277 (3.9) 1059 (3.8) .000
Region
Midwest 10,184 (25.7) 8646 (26.4) 6972 (25.3) .011
Northeast 9189 (23.2) 7319 (22.3) 6131 (22.3) .005
South 15,393 (38.8) 12,342 (37.6) 10,327 (37.5) .000
West 4889 (12.3) 4488 (13.7) 4102 (14.9) .000
Comorbid conditions
Chronic heart disease 14,464 (36.5) 12,313 (37.5) 9832 (35.7) .000
Congestive heart failure 12,229 (30.8) 10,846 (33.1) 8725 (31.7) .000
Peripheral vascular disease 13,547 (34.2) 11,395 (34.7) 8202 (29.8) .000
Cerebrovascular disease 6200 (15.6) 4728 (14.4) 3695 (13.4) .000
Chronic obstructive pulmonary disease 9089 (22.9) 8300 (25.3) 6470 (23.5) .000
Dementia 1751 (4.4) 1274 (3.9) 957 (3.5) .000
Paralysis 1243 (3.1) 723 (2.2) 599 (2.2) .000
Diabetes 9508 (24.0) 8538 (26.0) 7228 (26.3) .000
Chronic renal failure 2576 (6.5) 2469 (7.5) 4558 (16.6) .000
Cirrhodites 194 (0.5) 199 (0.6) 179 (0.7) .015
Liver disease 86 (0.2) 62 (0.2) 79 (0.3) .036
Ulcer disease 1424 (3.6) 1062 (3.2) 651 (2.4) .000
Rheumatologic disorder 1143 (2.9) 927 (2.8) 927 (3.4) .000
AIDS 3 (0.0) 4 (0.0) 19 (0.1) .000
Cancer 3478 (8.8) 3257 (9.9) 2730 (9.9) .000
Atrial ﬁbrillation 13,910 (35.1) 12,736 (38.8) 11,131 (40.4) .000
Hypertension 20,658 (52.1) 19,851 (60.5) 17,213 (62.5) .000
Hyperlipidemia 4781 (12.1) 7601 (23.2) 8837 (32.1) .000
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patients undergoing intervention for limb salvage during
their ALI hospitalization increased from 66.6% in 1998
to 74.9% in 2009 (P < .001 for trend). There was a marked
shift from open to endovascular limb salvage procedures
during the study period (Fig 2). The proportion of pa-
tients undergoing open surgery declined from 57.1% in
1998 to 51.6% in 2009 (P for trend < .001). Concomi-
tantly, the percentage of patients undergoing endovascular
therapy increased from 15.0% in 1998 to 33.1% in 2009
(P for trend < .001).
Trends in amputation rates. In-hospital amputations
rates did not change over time and were 8.1% in 1998
and 6.4% in 2009 (P for trend not signiﬁcant) (Fig 3).
Thirty-day amputation rates decreased from 10.4% in
1998 to 8.1% in 2009 (P for trend < .001). Predictors of
30-day amputation included black race, male gender,
advanced age, diabetes, and a history of peripheral
vascular disease. A history of atrial ﬁbrillation and a his-
tory of hyperlipidemia were associated with a decreased
risk of amputation (Table II and Supplementary Table I,
online only).In addition, 1-year amputation rates for ALI decreased
over time from 14.8% in 1998 to 11.0% in 2008 (P for
trend < .001). Predictors of 1-year amputation included
black race, male gender, diabetes, and a history of peri-
pheral vascular disease (Table III and Supplementary
Table II, online only).
Trends in mortality. In-hospital mortality for patients
with ALI decreased over time from 12.1% in 1998 to 9.0%
in 2009 (P for trend < .001). The 30-day mortality for ALI
remained unchanged over time at 18.3% in 1998 to 19.2%
in 2008. Predictors of 30-day mortality included advanced
age, chronic renal failure, dementia, cancer, and atrial
ﬁbrillation. Black race, male gender, and undergoing
endovascular or surgical intervention were associated with
lower 30-day mortality (Table IV and Supplementary
Table III, online only).
The overall risk-adjusted 1-year mortality for ALI
remained unchanged at 41.0% in 1998 to 42.0% in 2008
(Fig 4). Predictors of 1-year mortality for ALI included
advanced age, congestive heart failure, dementia, chronic
renal failure, and atrial ﬁbrillation. As with 30-day mortality,
black race, male gender, and undergoing endovascular
Fig 2. Trends in surgery and endovascular therapy (EVT) for the treatment of acute lower extremity ischemia (ALI) in
the U.S. Medicare population from 1998 to 2009.
Fig 1. Age-adjusted incidence of acute lower extremity ischemia (ALI) in the U.S. Medicare population from 1998
to 2009.
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1-year mortality (Table V and Supplementary Table IV,
online only).
Trends in amputation-free survival. In-hospital
amputation-free survival for all patients increased over
time from 81.2% in 1998 to 85.4% in 2009 (P for trend <
.001). However, 30-day amputation-free survival remained
stable (73.5% in 1998 to 74.5% in 2008; trend not signif-
icant), as did 1-year amputation-free survival (51.8% in
1998 to 52.3% in 2009; trend not signiﬁcant) (Fig 5).
DISCUSSION
The incidence of ALI in the U.S. Medicare population
has decreased signiﬁcantly in the past decade. During this
time, the use of endovascular therapy for the treatment
of ALI has increased signiﬁcantly, whereas the use of con-
ventional surgical therapy has decreased. Despite improve-
ments in amputation rates, mortality after presentation
with ALI remains signiﬁcant and unchanged after hospitaldischarge. In addition, whereas there have been signiﬁcant
improvements in in-hospital amputation-free survival rates,
there have been no concomitant improvements in
amputation-free survival rates after hospital discharge.
Prior population-based studies evaluating the incidence
of ALI during the past several decades have reported vari-
able results. National data from Sweden in the 1980s re-
ported an incidence of 9 per 100,000 for the entire
population and 180 per 100,000 in patients older than
90 years.4 Additional data from Sweden in the 1990s re-
ported an incidence of 13 per 100,000,8 whereas studies
from the United Kingdom previously reported incidence
rates of 3.7 per 100,00017 and 14 per 100,000.5 No prior
studies have reported on the incidence of ALI in the U.S.
Medicare population. Given that these prior studies
focused on the overall incidence of ALI in general popula-
tions of all ages, the incidence of 26 per 100,000 reported
herein appears reasonable for the Medicare population
aged 65 years and older. Although there is no clear
Fig 3. In-hospital, 30-day, and 1-year amputation rates for acute lower extremity ischemia (ALI) in the U.S. Medicare
population from 1998 to 2009.
Table II. Independent predictors of 30-day amputation
by multivariable analysis
OR 95% CI P value
Black race 2.01 1.89-2.15 .00
Peripheral vascular disease 1.90 1.81-2.00 .00
Dementia 1.63 1.49-1.79 .00
Rheumatologic disease 1.59 1.42-1.78 .00
Paralysis 1.40 1.23-1.58 .00
Male gender 1.32 1.26-1.39 .00
Age $85 years 1.30 1.19-1.42 .00
Other nonwhite race 1.27 1.14-1.42 .00
Diabetes 1.25 1.18-1.32 .00
South region 1.19 1.12-1.26 .00
Cerebrovascular disease 1.17 1.1-1.25 .00
Ulcer disease 1.15 1.03-1.29 .02
Age 80-84 years 1.14 1.04-1.25 .01
Chronic renal failure 1.09 1.01-1.18 .02
West region 1.09 1.01-1.18 .03
Cancer 1.08 1.01-1.17 .03
Congestive heart failure 1.06 1.01-1.13 .03
Atrial ﬁbrillation 0.91 0.87-0.96 .00
Hypertension 0.91 0.87-0.96 .00
Chronic heart disease 0.87 0.82-0.92 .00
Hyperlipidemia 0.69 0.65-0.74 .00
Endovascular therapy at
presentation
0.60 0.57-0.64 .00
Surgery at presentation 0.52 0.49-0.54 .00
CI, Conﬁdence interval; OR, odds ratio.
Table III. Independent predictors of 1-year amputation
by multivariable analysis
OR 95% CI P value
Black race 2.31 2.18-2.44 .00
Peripheral vascular disease 2.03 1.94-2.12 .00
Rheumatologic disease 1.57 1.42-1.73 .00
Dementia 1.51 1.38-1.64 .00
Diabetes 1.41 1.35-1.48 .00
Male gender 1.35 1.30-1.41 .00
Other nonwhite race 1.35 1.23-1.48 .00
Paralysis 1.31 1.17-1.47 .00
Ulcer disease 1.19 1.07-1.31 .00
Chronic renal failure 1.18 1.10-1.26 .00
Age $85 years 1.17 1.08-1.27 .00
Cerebrovascular disease 1.12 1.05-1.18 .00
South region 1.10 1.04-1.15 .00
Age 80-84 years 1.08 1.00-1.17 .06
Chronic heart disease 0.89 0.85-0.93 .00
Atrial ﬁbrillation 0.86 0.82-0.90 .00
Hyperlipidemia 0.73 0.69-0.77 .00
Endovascular therapy at presentation 0.73 0.69-0.76 .00
Surgery at presentation 0.63 0.60-0.65 .00
CI, Conﬁdence interval; OR, odds ratio.
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time, it may be due in part to an increased awareness and
subsequent increase in the secondary prevention of
different manifestations of cardiovascular disease during
this period.18-20 Furthermore, during this period, more pa-
tients with cardiac dysrhythmias, speciﬁcally atrial ﬁbrilla-
tion, were diagnosed and treated with anticoagulation,
reducing the rates of embolic events for a proportion of
this patient population.21,22 Also of note, the decrease in
incidence was not as pronounced in the female population
compared with the male population, perhaps in part
because awareness of peripheral vascular disease in womenhas lagged behind that of men. In addition, it has been pre-
viously demonstrated that although women have fewer
overall admissions for peripheral vascular disease and fewer
interventions, they have higher rates of emergent admis-
sions.23 Although causality has not been demonstrated,
this may be due to the fact that fewer elective procedures
are done for women, placing them at higher risk for acute
events.
Whereas the diffusion of endovascular therapy in the
treatment of acute limb ischemia has not been well charac-
terized, since its advent in the mid-1990s, the use of endo-
vascular therapy for the treatment of chronic lower
extremity peripheral arterial disease has increased markedly
with a concomitant decrease in surgical interventions.24-28
These practice pattern shifts, from open surgical to
endovascular interventions, have been demonstrated in
Table IV. Independent predictors of 30-day mortality
by multivariable analysis
OR 95% CI P value
Age $85 years 2.83 2.60-3.07 .00
Liver disease 1.91 1.38-2.64 .00
Dementia 1.79 1.66-1.92 .00
Cancer 1.78 1.68-1.87 .00
Age 80-84 years 1.74 1.59-1.89 .00
Chronic renal failure 1.55 1.46-1.64 .00
Age 75-79 years 1.41 1.29-1.54 .00
Paralysis 1.39 1.26-1.53 .00
Congestive heart failure 1.38 1.32-1.44 .00
Cerebrovascular disease 1.37 1.30-1.43 .00
Age 70-74 years 1.24 1.13-1.36 .00
Atrial ﬁbrillation 1.21 1.16-1.25 .00
Chronic obstructive
pulmonary disease
1.19 1.14-1.24 .00
West region 1.12 1.06-1.19 .00
Midwest region 1.08 1.03-1.14 .00
South region 1.06 1.01-1.11 .01
Chronic heart disease 1.05 1.01-1.09 .02
Diabetes 0.95 0.91-0.99 .01
Other nonwhite race 0.86 0.78-0.94 .00
Male gender 0.82 0.79-0.85 .00
Hypertension 0.80 0.76-0.83 .00
Black race 0.72 0.67-0.77 .00
Hyperlipidemia 0.65 0.62-0.69 .00
Endovascular therapy at
presentation
0.64 0.62-0.66 .00
Surgery at presentation 0.61 0.58-0.64 .00
CI, Conﬁdence interval; OR, odds ratio.
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(NIS),25,26 and several state databases.27,28 Among the
general Medicare population, the rate of overall lower ex-
tremity vascular procedures nearly doubled between 1996
and 2006, with endovascular interventions increasing
threefold and bypass surgeries decreasing by 42%; major
amputations decreased by nearly 30% in that time. Howev-
er, there is no clear causal link between these trends.24 For
patients speciﬁcally presenting with ALI, we found these
trends to be similar although not as pronounced. In partic-
ular, although the percentage of ALI patients undergoing
endovascular interventions doubled during the study
period, the percentage of patients undergoing open surgi-
cal procedures decreased far less and remained greater
than 50%. One possible explanation is that unlike in the
chronic disease setting, the severity of ischemia in ALI
often does not allow the time necessary for endovascular
techniques to restore arterial ﬂow to the lower extremity,
resulting in a signiﬁcant number of patients still requiring
open surgical intervention for limb salvage.
An important ﬁnding of the current study was that
despite the reduction in ALI incidence and the increase in
the ratio of endovascular to surgical interventions for ALI,
the impact on short-term and long-term outcomes was
mixed. During the decade, in-hospital amputation rates
remained stable, whereas amputation rates after discharge
(at both 30 days and 1 year) declined signiﬁcantly. At the
same time, though, in-hospital mortality declinedsigniﬁcantly, whereas 30-day and 1-year mortality rates did
not show concomitant improvements. Amputation-free sur-
vival rates followed mortality trends, with signiﬁcant short-
term improvements but an absence of concomitant longer
term improvements after hospital discharge. The reasons
for these disparate trends are not entirely clear and are likely
to be multifactorial.
Whereas short-term, in-hospital amputation rates did
not decline, the signiﬁcant reductions in 30-day and
1-year amputation rates are likely to be related to multiple
factors. Increased use of endovascular interventions may
have contributed to these improvements; however, as
with prior reviews in the setting of chronic disease, no
deﬁnitive causal relationship can be established. Given
that the amputation rates declined after discharge, it is
likely that better treatment of the comorbidities associated
with ALI has contributed to these improved longer term
outcomes. Speciﬁcally, increased treatment of hyperlipid-
emia, diabetes, and coronary heart disease along with
smoking cessation efforts has been associated with
improved outcomes after lower extremity interven-
tions.29,30 Despite these improvements, it is evident that
a signiﬁcant proportion of patients continue to be at risk
of limb loss beyond the perioperative period.
Further, despite the declines in amputation rates
demonstrated here and for patients with chronic lower
extremity peripheral arterial disease, there remain signiﬁcant
differences in the patients undergoing amputations. Specif-
ically, black race has previously been shown to be an inde-
pendent predictor of amputation both among Medicare
beneﬁciaries with chronic lower extremity ischemia31 and
for patients presenting with ALI from the NIS database.32
Our analyses conﬁrmed these earlier studies, which demon-
strated that in-hospital amputation rates were higher
among blacks, but also importantly extended these previ-
ous works by demonstrating that black race is the most sig-
niﬁcant independent predictor of amputation after
presentation with ALI in the Medicare population at
both 30 days and 1 year. Clearly, more work is needed
to understand the drivers of these disparities.
Turning to survival after ALI, although in-hospital
mortality rates fell during the study period, these rates
now exceed the rates of amputation for ALI. The decline
in in-hospital mortality has been previously demonstrated
in a review of NIS data whereby these rates crossed in
the late-1990s.6 However, no previous study has reported
on 30-day or 1-year mortality rates after presentation with
ALI. Our study adds an important piece of information
about the longer term prognosis after ALI: despite declines
in in-hospital mortality, 30-day and 1-year mortality rates
have not improved signiﬁcantly and remain impressively
high (19% and 42%, respectively). Despite the fact that
more ALI patients are undergoing either open or endovas-
cular revascularization procedures and more of these pa-
tients are being discharged alive from the hospital, we are
not seeing concomitant longer term survival beneﬁts.
Certainly, there may be some degree of selection bias
contributing to these ﬁndings in that more medically ill
Fig 4. In-hospital, 30-day, and 1-year mortality rates for acute lower extremity ischemia (ALI) in the U.S. Medicare
population from 1998 to 2009.
Table V. Independent predictors of 1-year mortality by
multivariable analysis
OR 95% CI P value
Age $85 years 3.21 3.02-3.41 .00
Cancer 2.47 2.35-2.59 .00
Dementia 2.28 2.11-2.46 .00
Chronic renal failure 2.07 1.97-2.18 .00
Liver disease 1.99 1.46-2.73 .00
Age 80-84 years 1.82 1.72-1.94 .00
Congestive heart failure 1.70 1.64-1.76 .00
Paralysis 1.59 1.45-1.74 .00
Cirrhodites 1.42 1.17-1.72 .00
Age 75-79 years 1.38 1.30-1.46 .00
Cerebrovascular disease 1.33 1.27-1.39 .00
Chronic obstructive pulmonary
disease
1.28 1.24-1.33 .00
Atrial ﬁbrillation 1.28 1.24-1.32 .00
Rheumatologic disease 1.23 1.14-1.34 .00
Age 70-74 years 1.14 1.07-1.21 .00
Diabetes 1.11 1.07-1.15 .00
Ulcer disease 1.10 1.02-1.19 .02
Peripheral vascular disease 1.07 1.04-1.11 .00
Male gender 0.93 0.90-0.96 .00
Black race 0.92 0.87-0.96 .00
Hypertension 0.84 0.81-0.87 .00
Surgery at presentation 0.75 0.73-0.77 .00
Endovascular therapy at
presentation
0.70 0.67-0.72 .00
Hyperlipidemia 0.63 0.61-0.65 .00
CI, Conﬁdence interval; OR, odds ratio.
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the increased use of less invasive endovascular techniques,
allowing discharge. Regardless, it is evident that long-
term mortality after ALI remains very poor, with more
than 40% of patients expiring at 1 year. Combining the
ALI end points of amputation and mortality, we found
that amputation-free survival trends have mirrored mortal-
ity trends with signiﬁcant improvements in in-hospital rates
but no concomitant improvements in 30-day or 1-year
rates. At 1 year, just more than 50% of patients were alivewith an intact limb, demonstrating that despite technologic
advances in treatment and the increased use of these treat-
ments in practice, ALI remains a high-morbidity, high-
mortality medical event.
The data presented here, speciﬁcally the striking 1-year
mortality rates and the mortality-driven 1-year amputation-
free survival rates, add to the contemporary knowledge of
ALI as the only recent nationwide database review to
examine outcomes beyond hospitalization. For patients
presenting with ALI, management and decision-making
remain challenging and have not been simpliﬁed with the
addition of endovascular therapy and its increasing use.
Although treatment will always need to be individualized,
these data emphasize the need to examine the patient as
a whole, particularly with regard to expected survival, given
the overall poor survival rates at 1 year for patients present-
ing with ALI.
The primary limitation of this study relates to its reli-
ance on administrative claims data. Our study relied on
hospitalization principal discharge diagnosis codes to iden-
tify ALI events. Inherent to our study is reliance on accu-
rate coding, and inaccurate coding is one of the major
limitations of use of diagnosis codes to identify patients
for study inclusion. Also, patients enrolled in a Medicare
health maintenance organization during the study period
were excluded as previously discussed on the basis of the
concern that MedPAR data may not capture complete
health care claims data for these individuals. Although
these patients represent a small proportion of the total
Medicare population, there is a possibility that some bias
may have resulted from exclusion of these patients. In addi-
tion, for this study, only hospitalized patients were
reviewed, and there is likely a very small percentage of pa-
tients with ALI who are being treated at outpatient facil-
ities and subsequently are not included. However, despite
increases in the spectrum of patients treated at such facil-
ities, it is unlikely that a signiﬁcant proportion of patients
with true ALI are being cared for at these facilities on an
outpatient basis. The extent to which there have been
Fig 5. In-hospital, 30-day, and 1-year amputation-free survival rates for acute lower extremity ischemia (ALI) in the
U.S. Medicare population from 1998 to 2009.
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ity arterial disease during the study period may have
affected reported incidence rates. It is possible, therefore,
that trends in the incidence of ALI hospitalizations may
be decreasing to a lesser extent than reported here if a
changing proportion of patients have been miscoded with
ICD-9 codes conventionally used for chronic disease. Use
of the “thrombosis and embolism” codes along with an
admission status of “urgent” or “emergent” should but
may not entirely have limited this misclassiﬁcation to
most clearly identify those Medicare beneﬁciaries who pre-
sented with an acutely ischemic limb. In addition, the use
of these codes does not allow separate analyses of patients
presenting with ischemia due to an embolism and of pa-
tients presenting with ischemia due to in situ thrombosis.
Furthermore, some components of patients’ histories
are not recorded in the Medicare claims data set, specif-
ically previous surgical history and tobacco use, both of
which may play a signiﬁcant role in the outcomes after pre-
sentation with ALI. In addition, procedural data are limited
within the data set speciﬁcally, and as such, patients who
underwent both an open and endovascular procedure
were excluded from review as the details including the
timing of these procedures are not available from the Medi-
care database. These may have been performed sequen-
tially, concomitantly, or days apart, and unfortunately,
another limitation of using administrative claims data is
determining these details. With regard to amputation as
an end point, only major amputations above the ankle
were included in this study. Although exclusion of minor
amputations may represent a limitation of this study, such
amputations have a markedly lesser impact on morbidity
and mortality and are not conventionally included in
deﬁning limb salvage.
Another important limitation is that this study does not
elucidate any causal relationships between the decline in
ALI incidence, growth in endovascular therapy use, and
subsequent trends in short- and long-term amputationand mortality rates. More research is needed to better
elucidate these relationships. Despite these limitations,
this analysis represents the only contemporary report on
ALI trends among this patient population that speciﬁcally
includes long-term outcomes after hospital discharge.
CONCLUSIONS
The incidence of ALI in the U.S. Medicare population
has declined during the past decade. During this time, an
increased proportion of patients have undergone an inter-
vention for limb salvage, with a marked increase in the
use of endovascular techniques. Although there have
been improvements in overall amputation rates for these
patients, mortality rates remain signiﬁcant and have not
improved after hospital discharge.
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Supplementary Table I (online only). Predictors of
30-day amputation by univariate analysis
OR 95% CI P value
Atrial ﬁbrillation 0.93 0.88-0.97 .00
Age 65-69 years 0.97 0.91-1.03 .30
Age 70-74 years 0.95 0.90-1.01 .11
Age 75-79 years 0.96 0.91-1.01 .15
Age 80-84 years 0.98 0.93-1.03 .43
Age $85 years 1.09 1.04-1.15 .00
AIDS 2.29 0.77-6.80 .14
Black race 2.25 2.11-2.39 .00
Cancer 1.12 1.04-1.20 .00
Cerebrovascular disease 1.38 1.31-1.47 .00
Chronic heart disease 1.06 1.02-1.11 .01
Congestive heart failure 1.19 1.14-1.25 .00
Chronic renal failure 1.34 1.25-1.43 .00
Cirrhodites 1.30 1.00-1.69 .05
Chronic obstructive pulmonary
disease
1.20 1.14-1.26 .00
Dementia 2.06 1.89-2.25 .00
Diabetes 1.36 1.30-1.43 .00
Endovascular therapy on
presentation
0.66 0.62-0.70 .00
Hyperlipidemia 0.73 0.69-0.78 .00
Hypertension 1.14 1.09-1.20 .00
Liver disease 1.45 0.97-2.16 .07
Male gender 1.29 1.24-1.35 .00
Midwest region 0.87 0.83-0.92 .00
Northeast region 0.90 0.86-0.95 .00
Paralysis 1.73 1.54-1.94 .00
Peripheral vascular disease 1.84 1.76-1.92 .00
Other nonwhite race 1.27 1.15-1.42 .00
Rheumatologic disease 1.54 1.38-1.72 .00
South region 1.23 1.17-1.28 .00
Surgery at presentation 0.58 0.55-0.61 .00
Ulcer disease 1.37 1.23-1.53 .00
West region 0.95 0.89-1.01 .10
White race 0.50 0.47-0.53 .00
CI, Conﬁdence interval; OR, odds ratio.
Supplementary Table II (online only). Predictors of
1-year amputation by univariate analysis
OR 95% CI P value
Atrial ﬁbrillation 0.86 0.82-0.89 .00
Age 65-69 years 1.08 1.03-1.14 .00
Age 70-74 years 1.07 1.02-1.12 .01
Age 75-79 years 1.04 0.99-1.09 .13
Age 80-84 years 0.96 0.92-1.01 .10
Age $85 years 0.94 0.90-0.98 .00
AIDS 2.08 0.76-5.69 .15
Black race 2.60 2.46-2.75 .00
Cancer 1.04 0.98-1.11 .22
Cerebrovascular disease 1.31 1.25-1.38 .00
Chronic heart disease 1.12 1.08-1.17 .00
Congestive heart failure 1.16 1.12-1.21 .00
Chronic renal failure 1.50 1.41-1.59 .00
Cirrhodites 1.15 0.91-1.46 .25
Chronic obstructive pulmonary
disease
1.20 1.15-1.26 .00
Dementia 1.77 1.64-1.92 .00
Diabetes 1.59 1.53-1.66 .00
Endovascular therapy on
presentation
0.76 0.73-0.80 .00
Hyperlipidemia 0.82 0.78-0.86 .00
Hypertension 1.22 1.17-1.27 .00
Liver disease 1.25 0.86-1.80 .24
Male gender 1.37 1.32-1.42 .00
Midwest region 0.87 0.84-0.91 .00
Northeast region 0.96 0.92-1.01 .10
Paralysis 1.56 1.40-1.73 .00
Peripheral vascular disease 2.07 1.99-2.15 .00
Other nonwhite race 1.36 1.24-1.49 .00
Rheumatologic disease 1.52 1.38-1.67 .00
South region 1.20 1.15-1.24 .00
Surgery at presentation 0.68 0.66-0.71 .00
Ulcer disease 1.42 1.29-1.56 .00
West region 0.91 0.86-0.96 .00
White race 0.44 0.42-0.46 .00
CI, Conﬁdence interval; OR, odds ratio.
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Supplementary Table III (online only). Predictors of
30-day mortality by univariate analysis
OR 95% CI P value
Atrial ﬁbrillation 1.70 1.64-1.76 .00
Age 65-69 years 0.46 0.44-0.49 .00
Age 70-74 years 0.54 0.52-0.57 .00
Age 75-79 years 0.67 0.64-0.70 .00
Age 80-84 years 0.93 0.90-0.97 .00
Age $85 years 2.34 2.27-2.42 .00
AIDS 0.47 0.11-2.01 .31
Black race 0.66 0.62-0.71 .00
Cancer 1.57 1.50-1.66 .00
Cerebrovascular disease 1.62 1.55-1.69 .00
Chronic heart disease 1.21 1.17-1.25 .00
Congestive heart failure 1.80 1.74-1.86 .00
Chronic renal failure 1.56 1.48-1.64 .00
Cirrhodites 1.44 1.19-1.76 .00
Chronic obstructive pulmonary
disease
1.22 1.18-1.27 .00
Dementia 2.74 2.56-2.94 .00
Diabetes 0.95 0.91-0.98 .01
Endovascular therapy on
presentation
0.61 0.58-0.64 .00
Hyperlipidemia 0.64 0.61-0.67 .00
Hypertension 1.07 1.03-1.10 .00
Liver disease 2.09 1.57-2.79 .00
Male gender 0.70 0.67-0.72 .00
Midwest region 1.04 1.01-1.08 .03
Northeast region 1.01 0.97-1.05 .65
Paralysis 1.92 1.76-2.10 .00
Peripheral vascular disease 0.94 0.91-0.97 .00
Other nonwhite race 0.85 0.77-0.93 .00
Rheumatologic disease 1.11 1.01-1.22 .04
South region 0.93 0.89-0.96 .00
Surgery at presentation 0.71 0.69-0.74 .00
Ulcer disease 1.18 1.08-1.29 .00
West region 1.07 1.02-1.12 .00
White race 1.42 1.34-1.50 .00
CI, Conﬁdence interval; OR, odds ratio.
Supplementary Table IV (online only). Predictors of
1-year mortality by univariate analysis
OR 95% CI P value
Atrial ﬁbrillation 2.01 1.96-2.07 .00
Age 65-69 years 0.46 0.45-0.48 .00
Age 70-74 years 0.52 0.50-0.54 .00
Age 75-79 years 0.68 0.66-0.70 .00
Age 80-84 years 1.01 0.98-1.05 .45
Age $85 years 2.50 2.43-2.57 .00
AIDS 1.29 0.55-3.05 .56
Black race 0.84 0.80-0.88 .00
Cancer 2.09 2.00-2.19 .00
Cerebrovascular disease 1.73 1.66-1.79 .00
Chronic heart disease 1.40 1.36-1.44 .00
Congestive heart failure 2.41 2.34-2.47 .00
Chronic renal failure 2.28 2.18-2.38 .00
Cirrhodites 1.85 1.56-2.19 .00
Chronic obstructive pulmonary
disease
1.44 1.40-1.49 .00
Dementia 3.65 3.40-3.92 .00
Diabetes 1.21 1.17-1.24 .00
Endovascular therapy on
presentation
0.66 0.64-0.69 .00
Hyperlipidemia 0.70 0.68-0.72 .00
Hypertension 1.30 1.26-1.33 .00
Liver disease 2.57 1.95-3.40 .00
Male gender 0.77 0.75-0.79 .00
Midwest region 0.99 0.96-1.02 .57
Northeast region 1.11 1.07-1.14 .00
Paralysis 2.23 2.05-2.42 .00
Peripheral vascular disease 1.14 1.11-1.18 .00
Other nonwhite race 0.92 0.86-0.99 .02
Rheumatologic disease 1.29 1.20-1.39 .00
South region 0.92 0.90-0.95 .00
Surgery at presentation 0.82 0.80-0.84 .00
Ulcer disease 1.46 1.36-1.57 .00
West region 1.02 0.98-1.06 .28
White race 1.17 1.12-1.21 .00
CI, Conﬁdence interval; OR, odds ratio.
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